Point: Pulmonary inhalation of insulin: Another "brick in the wall"

Diabetes Care

Volumn 30, Issue 2, 2007, Pages 439-443

  Cefalu, William T ^a   Nathan, David M ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCOSE; HEMOGLOBIN A1C; HORMONE ANTAGONIST; INSULIN; INSULIN LISPRO; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG FUNCTION TEST; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; PATIENT SATISFACTION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LUNG; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS;

EID: 33846687105     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2163     Document Type: Review

References (0)